Keros Therapeutics, Inc. (NASDAQ:KROS - Get Free Report)'s stock price dropped 3.9% during trading on Thursday . The company traded as low as $14.27 and last traded at $14.07. Approximately 81,809 shares traded hands during mid-day trading, a decline of 90% from the average daily volume of 841,059 shares. The stock had previously closed at $14.64.
Analyst Ratings Changes
A number of research firms have issued reports on KROS. Scotiabank reduced their target price on shares of Keros Therapeutics from $41.00 to $26.00 and set a "sector outperform" rating for the company in a research note on Monday, May 12th. Wedbush reiterated a "neutral" rating and issued a $15.00 price objective on shares of Keros Therapeutics in a report on Friday. Wells Fargo & Company lowered their target price on shares of Keros Therapeutics from $28.00 to $26.00 and set an "overweight" rating on the stock in a research report on Thursday, February 27th. HC Wainwright reduced their price target on Keros Therapeutics from $40.00 to $25.00 and set a "buy" rating for the company in a research report on Thursday, May 8th. Finally, Truist Financial decreased their price target on Keros Therapeutics from $43.00 to $25.00 and set a "buy" rating for the company in a research note on Wednesday, April 9th. Six research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. According to MarketBeat, Keros Therapeutics presently has a consensus rating of "Moderate Buy" and an average price target of $37.00.
View Our Latest Analysis on KROS
Keros Therapeutics Stock Performance
The firm has a 50 day moving average price of $13.00 and a two-hundred day moving average price of $19.14. The company has a market capitalization of $595.42 million, a P/E ratio of -2.81 and a beta of 1.32.
Keros Therapeutics (NASDAQ:KROS - Get Free Report) last announced its quarterly earnings results on Tuesday, May 6th. The company reported $3.62 earnings per share for the quarter, beating analysts' consensus estimates of ($0.01) by $3.63. Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. The firm had revenue of $211.25 million for the quarter, compared to analysts' expectations of $84.62 million. During the same period in the prior year, the business posted ($1.21) earnings per share. On average, equities analysts expect that Keros Therapeutics, Inc. will post -4.74 earnings per share for the current year.
Insider Transactions at Keros Therapeutics
In other news, major shareholder Adar1 Capital Management, Llc bought 934,258 shares of the business's stock in a transaction dated Wednesday, April 9th. The stock was bought at an average price of $10.13 per share, for a total transaction of $9,464,033.54. Following the completion of the purchase, the insider now owns 4,392,737 shares of the company's stock, valued at approximately $44,498,425.81. The trade was a 27.01% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 20.60% of the stock is owned by insiders.
Institutional Inflows and Outflows
A number of large investors have recently added to or reduced their stakes in the business. FNY Investment Advisers LLC acquired a new position in Keros Therapeutics in the first quarter valued at about $25,000. CWM LLC increased its stake in shares of Keros Therapeutics by 10,157.7% in the 1st quarter. CWM LLC now owns 2,667 shares of the company's stock valued at $27,000 after acquiring an additional 2,641 shares during the last quarter. AlphaQuest LLC raised its position in shares of Keros Therapeutics by 469.0% in the 4th quarter. AlphaQuest LLC now owns 3,596 shares of the company's stock valued at $57,000 after acquiring an additional 2,964 shares during the period. Virtus ETF Advisers LLC boosted its stake in Keros Therapeutics by 107.5% during the 4th quarter. Virtus ETF Advisers LLC now owns 3,857 shares of the company's stock worth $61,000 after acquiring an additional 1,998 shares during the last quarter. Finally, KLP Kapitalforvaltning AS bought a new position in Keros Therapeutics during the 4th quarter worth approximately $90,000. 71.56% of the stock is currently owned by institutional investors and hedge funds.
About Keros Therapeutics
(
Get Free Report)
Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.
Featured Articles
Before you consider Keros Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Keros Therapeutics wasn't on the list.
While Keros Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
